Jennifer Arthur

Vice President, Finance

Jennifer Arthur brings more than 12 years of finance experience in the pharmaceutical and biotechnology industries. Joining COI Pharmaceuticals in 2013 as vice president of finance, Ms. Arthur also serves as the Controller for Avelas Biosciences, RQX Pharmaceuticals, and Sova Pharmaceuticals.

Most recently, she served as Controller for Cadence Pharmaceuticals, a publicly traded pharmaceutical company. Over the span of eight years, her efforts took a small private development start-up of three employees and helped grow it into a public commercial entity of over two hundred employees. Ms. Arthur played an instrumental role in the company’s IPO and later established the infrastructure to support a sales force and product distribution. Prior to that, Ms. Arthur held roles as the director of finance for Sorrento Associates a venture capital company and controller for Ancile Pharmaceuticals, Inc. and Next Proteins, Inc.

Ms. Arthur received a B.A. in Economics from the University of California, Los Angeles.

in the news

  • Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK

    read more
  • That’s a wrap on 2018…hello 2019!

    read more
  • Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

    read more